Core Viewpoint - Hualan Biological Engineering has intensified its strategy in AI-driven pharmaceuticals by expanding its AI Medical Expert Committee and electing new members, indicating a commitment to leveraging AI in drug development [1][2] Group 1: Company Developments - Hualan Biological announced the addition of Hu Tony Ye to its AI Medical Expert Committee, enhancing the committee's expertise with his extensive background in biomedical engineering and industry connections [2] - The company plans to invest 20 million yuan in Suzhou Kema Biotechnology, which is expected to benefit from the technological integration of its shareholders and Hualan's extensive client network [1][2] Group 2: Market Outlook - Huatai Securities forecasts a significant growth in the global AI-enabled drug development market, projecting an increase from $11.9 billion in 2023 to $74.6 billion by 2032, with a compound annual growth rate of 22.6% [3] - The report highlights that Hualan's core business is expected to maintain growth, particularly in its cartridge business, with revenue growth projected between 5% and 15% [3] Group 3: Financial Projections - Huatai Securities has raised its target price for Hualan from 39.46 yuan to 69.60 yuan, maintaining a "buy" rating based on the company's growth potential in AI pharmaceuticals and ongoing order fulfillment [4]

Investment Rating - The report maintains a "Buy" rating for the company [5][7]. Core Views - The company is expected to benefit from the continuous growth of its cartridge bottle components, with projected revenue growth in 2026 [1][4]. - The global AI-enabled drug development market is anticipated to grow from USD 11.9 billion in 2023 to USD 74.6 billion by 2032, with a compound annual growth rate (CAGR) of 22.6% [3]. - The establishment of a wholly-owned subsidiary and investment in Suzhou Kema Biotechnology are seen as strategic moves to enhance the company's capabilities in AI drug development [2][3]. Summary by Sections Investment Rating - The target price is set at RMB 69.60, reflecting a price-to-earnings (PE) ratio of 85x for 2026, which is a premium compared to the industry average [5][7]. Company Strategy - The company has made significant investments in AI drug development, including the establishment of an AI pharmaceutical committee and partnerships with technology firms [1][3]. - The company aims to leverage its extensive customer base of over 1,000 pharmaceutical companies across more than 40 countries to facilitate the commercialization of its AI-enabled drug development initiatives [2][3]. Financial Projections - Revenue is projected to reach RMB 896.34 million in 2026, with a year-on-year growth of 17.17% [11]. - The net profit attributable to the parent company is expected to be RMB 134.46 million in 2026, reflecting a 24.44% increase from the previous year [11]. - The company anticipates a stable performance in its core business of pharmaceutical rubber stoppers, with revenue growth expected to be between 5% and 15% [4].